When does Opdivo’s patent expire in Europe?
Opdivo (nivolumab) patent expiry in Europe depends on which right you mean (the original drug patents versus later-life-cycle patents) and which country you’re asking about. The key point is that medicines like Opdivo usually have multiple layers of protection—separate patents for the active ingredient, specific formulations or uses, and sometimes additional protections granted via supplementary protection certificates (SPCs)—so “the” expiry date is not a single universal day across Europe.
Why there isn’t one single “Opdivo patent expiry date” across Europe
European drug protection is handled through national systems and multiple patent instruments:
- Patents are filed and enforced at a national level (e.g., UK) or via European patent systems that still ultimately rely on national validation/enforcement.
- Supplementary protection certificates (SPCs) can extend exclusivity beyond the basic patent term to compensate for time spent during development and approval.
- Additional patents can be granted for improvements or specific medical uses, which can delay generic or biosimilar entry in certain jurisdictions even after earlier patents lapse.
What to check to find the real expiry date for your country
To determine when Opdivo’s exclusivity protection ends in a specific European country, you typically need to look up:
- The relevant patent numbers covering Opdivo in that jurisdiction.
- Whether an SPC was granted for those patents (and the SPC expiry).
- Any later patents that may still be in force.
How exclusivity differs from “patent expiry” in practice (biosimilars and market entry)
Even after a key patent ends, market entry timing can still be affected by:
- SPC expiry (often the main driver of “late” exclusivity in Europe).
- Other still-active patents for related claims (method-of-use, formulation, combination regimens).
- Regulatory market exclusivity rules, which are separate from patents and can delay launch even if patent claims no longer block entry.
If you tell me the country, I can narrow the answer
Europe is not one uniform answer for patent expiry. If you specify which jurisdiction you mean (for example: UK, Germany, France, Italy, Spain, or “EU-wide”), I can help map out what to look for (and which protection layer usually controls the timeline).